10-K · February 26, 2026
Lantheus’ 10-K emphasizes a strategy focused on PET radiodiagnostics and microbubbles, highlighted by multiple 2025 acquisitions (Life Molecular and Evergreen) and the post-period divestiture of its SPECT business to…
Earnings analysis · 10-Q
LNTH earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Lantheus reported a solid Q1 2026 with revenue of $377.3 million, exceeding estimates and achieving an EPS of $1.80, reflecting a 62.3% increase in net income year-over-year. However, gross profit declined slightly,…
Read full summary
Lantheus reported a solid Q1 2026 with revenue of $377.3 million, exceeding estimates and achieving an EPS of $1.80, reflecting a 62.3% increase in net income year-over-year. However, gross profit declined slightly, primarily due to price reductions for PYLARIFY despite strong revenues in new segments like Neuraceq and DEFINITY.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.8
- Segment
- Oncology
- Segment
- Neurology
- Segment
- Cardiology
- Segment
- Strategic Partnerships
What stood out
-
Q1 2026 Revenue Beat
Lantheus achieved revenue of $377.3 million, exceeding consensus estimates of $355.2 million.
-
Q1 2026 EPS Beat
The company reported EPS of $1.80, surpassing the estimated $1.19.
-
Strong Free Cash Flow
Positive operating cash flow of $125.1 million was recorded, compared to $107.6 million in Q1 2025.
-
Diverse Revenue Streams
New products Neuraceq and DEFINITY drove growth, with Neuraceq contributing $35.4 million in newly included revenues.
-
Strategic Business Sales
The sale of the SPECT business contributed $59.3 million to gains, bolstering cash reserves.
-
Increase in Accounts Payable
A timely increase in accounts payable helped improve cash flow management.
What to watch
-
Decline in PYLARIFY Sales
PYLARIFY revenues fell by $16.7 million (6.5%) year-over-year to $240.9 million due to pricing pressures.
-
Regulatory Timeline Risks for LNTH-2501
FDA extended the review of LNTH-2501's NDA, impacting expected timelines for product launch.
-
Integration Challenges Post-Acquisitions
The acquisitions of Evergreen and Lantheus Biosciences may face operational integration risks that could affect future performance.
Management's outlook
The company reaffirmed full-year guidance for revenue between $1.4 billion and $1.45 billion and adjusted EPS between $5.00 and $5.25.
Earlier filings 4
10-Q · May 7, 2025
Lantheus reported revenue of $372,764,000 for the three months ended March 31, 2025, up $2,789,000 versus $369,975,000 in Q1 2024, while diluted EPS fell to $1.02 from $1.87 a year ago. Gross margin was 63.8% and…
10-K · February 26, 2025
Lantheus describes a deliberate strategy to evolve into a fully integrated radiopharmaceutical company, expanding through targeted M&A and in‑licensing while commercializing core products (PYLARIFY, DEFINITY) and…
10-Q · July 31, 2024
Lantheus reported Q2 2024 revenue of $394.091M, up $72.391M (22.5%) versus Q2 2023, driven primarily by PYLARIFY growth. Gross margin was stable at 64.9% but operating margin and EPS compressed as operating expenses…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.